Hepatitis C Genotype Distribution in Türkiye; Are Genotypes Distributions Changing? A Meta-Analysis

Abstract

Backround: Hepatitis C virus is one of the leading causes of viral hepatitis in humans. It is clinically characterized by chronic hepatitis developing after acute infection. There are seven genotypes of HCV. Each genotype, numbered one to seven, has several subtypes. Genotype differences play a role in the course of HCV infection, basic pathological features, and response to treatment. In this study, we aimed to determine the genotype distribution of HCV in Türkiye and whether there is a change in the HCV genotype distribution over the years. Methods: PubMed, Scopus and TR Dizin databases are used to select the appropriate publications to use data in the study. 103 studies were included in this study. Of these, 32036 data were evaluated. This study protocol was developed keeping in view the requirements of the PRISMA guidelines. Result: A total of 32036 genotype data were found from the studies included in the evaluation. Genotype 1 (82.6%) was the most common genotype. The genotype distribution rates for genotype 2, genotype 3, genotype 4 and other groups are 3.9%, 8.7%, 3.9% and 0.9%, respectively. There was a significant difference between the genders Genotype 1 incidence is significantly higher in females compared to males, while genotypes 2 and 3 have a higher incidence in males. There was a significant difference between the regions for all genotypes. When the distribution was analyzed according to the years, there was a significant difference according to the years. After 2011, a significant decrease in genotype 1 and a significant increase in genotype 3 were detected. Conclusion: The most common HCV genotype in Türkiye is genotype 1. The most common genotype has not changed over the years, but we observed that the distribution of genotypes has changed at various rates. This may increase in the future for various reasons.

Keywords

• Hepatitis C
• HCV
• genotype
• Türkiye

Türkiye'de Hepatit C Genotip Dağılımı; Genotip Dağılımları Değişiyor mu? Bir Meta-Analiz

Abstract

Giriş: Hepatit C virüsü insanda viral hepatitin önde gelen nedenlerinden biridir. Klinik tablo akut enfeksiyondan sonra gelişen kronik hepatit ile karakterizedir. HCV’ nin yedi genotipi vardır. Birden yediye kadar numaralandırılan her bir genotipin de birkaç alt tipi bulunur. Genotip farklılıkları HCV enfeksiyonunun seyri, temel patolojik özellikleri ve tedaviye yanıtta rol oynar. Bu çalışmada, Türkiye'de HCV' nin genotip dağılımını ve HCV genotip dağılımında yıllara göre değişim olup olmadığını belirlemeyi amaçladık. Yöntemler: Çalışmada veri kullanmak için uygun yayınların seçilmesinde PubMed, Scopus ve TR Dizin veri tabanları kullanıldı. 103 çalışma bu çalışmaya dahil edilmiştir ve bunlar arasından 32036 veri değerlendirilmiştir. Bu çalışma protokolü PRISMA kılavuzlarının gereklilikleri göz önünde bulundurularak uygulandı. Sonuç: Değerlendirmeye alınan çalışmalarda toplam 32036 genotip verisi bulunmuştur. Genotip 1 (%82.6) en sık görülen genotip olmuştur. Genotip 2, genotip 3, genotip 4 ve diğer grup için genotip dağılımı oranları sırasıyla %3.9, %8.7, %3.9 ve %0.9’dur. Cinsiyetler arasında anlamlı fark bulunmuştur. Genotip 1 görülme sıklığı kadınlarda erkeklere göre anlamlı olarak daha yüksek iken, genotip 2 ve 3 erkeklerde daha fazla görülme sıklığına sahiptir. Tüm genotipler için bölgeler arasında anlamlı fark bulunmuştur. Yıllara göre dağılım incelendiğinde yıllara göre anlamlı fark bulunmuştur. 2011 yılından sonra genotip 1'de anlamlı azalma, genotip 3'te ise anlamlı artış tespit edilmiştir. Sonuç: Türkiye'de görülen en yaygın HCV genotipi genotip 1’dir. En yaygın görülen genotip yıllara göre değişmemiştir, ancak genotiplerin dağılımının çeşitli oranlarda değiştiğini gözlemledik. Bu durum gelecekte çeşitli nedenlerle artabilir.

Keywords

• Hepatit C
• HCV
• genotip
• Türkiye.

References

1. 1.Manns MP, Buti M, Gane E, et al. Hepatitis C virusinfection. Nat Rev Dis Primers. 2017;3:17006.
2. 2.National Center for Biotechnology Information(NCBI). Taxonomy Browser. Available from:https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=info&id=11103 (Access date:22.11.2022).
3. 3.Smith DB, Bukh J, Kuiken C, et al. Expandedclassification of hepatitis C virus into 7 genotypesand 67 subtypes: updated criteria and genotypeassignment web resource. Hepatology.2014;59(1):318-27.
4. 4.Ripoli M, Pazienza V. Impact of HCV geneticdifferences on pathobiology of disease. Expert RevAnti Infect Ther. 2011;9(9):747-59.
5. 5.World Healt Organization (WHO). Hepatitis C.2022. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (Access date:22.11.2022).
6. 6.Page MJ, McKenzie JE, Bossuyt PM, et al. ThePRISMA 2020 statement: an updated guideline forreporting systematic reviews. BMJ. 2021;372:n71
7. 7.Ağca H, Mıstık R, Kazak E. Distribution of HepatitisC Virus Genotypes in the South Marmara Region. JClin Anal Med. 2015;6(2): 190-2.
8. 8.Aksu HS, Kurtaran B, Onlen Y, et al. Association ofinsulin resistance, viral load, and adipokine levelswith liver histology in patients with chronichepatitis C: an observational, multicenter study inTurkey. Eur J Gastroenterol Hepatol.2012;24(12):1393-9.

9. 9.Aktaş E, Ogedey ED, Külah C, Beğendik Cömert F.Zonguldak bölgesinde hepatit C virusu genotipleri.Mikrobiyol Bul. 2010;44(4):647-50.
10. 10.Aktaş O, Özbek A, Aydın H, Özkülekci MB.Distribution of HCV Genotypes in Patients of withChronic Hepatitis C in the Eastern Anatolia Region.Viral Hepat J. 2014;20(3):91-4.
11. 11.Altindis M, Yilmaz S, Dikengil T, Acemoglu H,Hosoglu S. Seroprevalence and genotyping ofhepatitis B, hepatitis C and HIV among healthypopulation and Turkish soldiers in Northern Cyprus. World J Gastroenterol. 2006;12(42):6792-6.
12. 12.Altındiş M, Dal T, Akyar I, et al. Six-yeardistribution pattern of hepatitis C virus in Turkey: amulticentre study. Biotechnol Biotechnol Equip.2016;30(2):335-40.
13. 13.Altuğlu I, Sertöz R, Aksoy A, et al. Possibletransmission risks and genotype distribution ofhepatitis C virus infection in Western Turkey. Turk JGastroenterol. 2013;24(4):349-55.
14. 14.Altuglu I, Soyler I, Ozacar T, Erensoy S.Distribution of hepatitis C virus genotypes inpatients with chronic hepatitis C infection inWestern Turkey. Int J Infect Dis. 2008;12(3):239-44.
15. 15.Aydin OA, Yemisen M, Karaosmanoglu HK, et al.Low Prevalence of Hepatitis C Virus InfectionAmong HIV-Positive Patients: Data From a Large-Scale Cohort Study in Istanbul, Turkey. Hepat Mon.2014;14(8):e18128.
16. 16.Aşgın N, Satılmış Ş. An Evaluation of Hepatitis BVirus and Hepatitis C Virus Frequency and the Anti-hepatitis B Surface Seropositivity of Syrian Refugeesin the Karabük Province. Viral Hepat J.2019;25(3):84-7.
17. 17. Aşgın N, Satılmış Ş. Evaluation of hepatitis B virusand Hepatitis C virüs frequency in hemodialysispatients. Ann Med Res. 2019;26(12):3007-11.
18. 18.Atilla A, Duyar E, Bostancı F, Kılıç SS. PegylatedInterferon/Ribavirin dual therapy in patients withchronic Hepatitis C: results of 323 cases. J MicrobilInfect Dis. 2015;5(4):151-5.
19. 19.Aydın Ö. Genotype Distributions and Hepatitis BCoinfection in Hepatitis C Patients at a UniversityHospital. Viral Hepat J. 2021;27(1):13-8.
20. 20.Aydın NN, Aksoy F, Yavuz İ, et al. Efficacy ofDirect-acting Antivirals in Hemodialysis Patientswith Chronic Hepatitis C: A Real-life RetrospectiveStudy. Viral Hepat J. 2019;25 (3):105-8.
21. 21.Aygen B, Yildiz O, Akhan S, et al. Impact ofInterleukin 28B Genotype on the VirologicalResponses in Chronic Hepatitis C Treatment.Gastroenterology Res. 2014;7(5-6):123-30.
22. 22.Borcak D, Çağır Ü, Yalçıner A. Nevşehir İlindeHepatit C Virüs Genotip Dağılımı İle Serum AlaninAminotransferaz Ve Kantitatif Serum HCV RNADüzeyleri İlişkisi. ANKEM Derg. 2015;29(1):36-40.
23. 23. Bozkaya H, Bozdayi AM, Aslan N, et al. CirculatingIL-2 and IL-10 in chronic active hepatitis C withrespect to the response to IFN treatment. Infection.2000;28(5):309-13.
24. 24.Bulut ME, Topalca US, Murat A, et al. HCVGenotype Distribution of Patients with ChronicHepatitis C in Istanbul. Sisli Etfal Hastan Tip Bul.2021;55(1):86-92.
25. 25.Buruk CK, Bayramoğlu G, Reis A, et al. DoğuKaradeniz Bölgesi Hepatit C Hastalarında Hepatit CVirusu Genotiplerinin Belirlenmesi. Mikrobiyol Bul.2013;47(4):650-7.
26. 26.Cirit OS, Uzala Mızraklı A, Vurupalmaz Y, et al.Genotyping Distribution of Hepatitis C Virus inŞanlıurfa Province and Effect of Syrian Patients.Viral Hepat J. 2019;25(2):62-6.
27. 27.Çabalak M, Bal T. Intravenous Drug Use Ratesand Results of Direct-acting Antiviral Treatment inPrisoner Patients. Viral Hepat J. 2020;26(2):61-4.
28. 28.Caliskan A, Kirisci O, Ozkaya E, et al. Distributionand predominance of genotype 3 in hepatitis C virus carriers in the province of Kahramanmaras, Turkey. Hepat Mon. 2015;15(4):e25142.
29. 29.Çekın Y, Gür N, Çekın AH, Altuğlu İ, Yazan SertözR.Antalya Eğitim ve Araştırma Hastanesinde kronikhepatit C hastalarının genotip dağılımınınaraştırılması. Mikrobiyol Bul. 2014;48(3):484-90.
30. 30.Çetin Duran A, Kibar F, Çetiner S, Yaman A.Çukurova Üniversitesi Tıp Fakültesi Hastanesi’ndeHepatit C virus genotiplerinin ve HCV enfeksiyonubulaş yollarının belirlenmesi. Turk Hij Den BiyolDerg. 2017;74(3): 201-10.
31. 31.Çetin Duran A, Kaya Çetinkaya Ö, Sayıner AA, etal. Changes on Hepatitis C virus genotypedistribution in Western Turkey: Evaluation oftwelve-year data. Turk J Gastroenterol.2020;31(2):128-35.
32. 32.Çil T, Özekinci T, Göral V, Altınbaş A. GüneydoğuAnadolu Bölgesi’nde Hepatit C virüsü Genotipleri.Turkiye Klinikleri J Med Sci. 2007;27(4):496-500.
33. 33.Çizmeci Z. Kronik Hepatit C EnfeksiyonluHastalarda Hepatit C Virüs Genotiplerinin Dağılımı.Türk Mikrobiyol Cem Derg. 2016;46(1):27-32.
34. 34.Değertekin B, Demir M, Akarca US, et al. Real-world efficacy and safety of Ledipasvir + Sofosbuvirand Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvircombination therapies for chronic hepatitis C: ATurkish experience. Turk J Gastroenterol.2020;31(12):883-93.
35. 35.Demircili ME, Özdemir M, Feyzioğlu B, Baysal B.The Efficiency of Hepatitis C virus Core Antigen Test in the Diagnosis of Hepatitis C Infection. Viral HepatJ.2016;22(1):18-22.
36. 36.Dilek AR, Şahin K, Bahçeci İ, Dilek N. TheDifferent Distribution of Hepatitis C Virus Genotypes in Eastern Black Sea Region of Turkey. J MicrobBiochem Technol. 2013;5(4):92-4.
37. 37.Erensoy S, Göksel S, Akarca US, Özkahya M,Canatan D. Hepatit C Virüsünün Polimeraz ZincirReaksiyonu Ürünlerinin Doğrudan Dizi Analizi ileGenotiplemesi. Flora. 2002;7(2):104-11.
38. 38.Erman Daloğlu A, Parkan ÖM, Erdoğan A, et al.Damar İçi Madde Bağımlılığı Olan ve MaddeBağımlısı Olmayan Hastalar Arasında Hepatit CVirus (HCV) Genotiplerinin Dağılımı. Mikrobiyol Bul.2021;55(1):30-40.
39. 39.Ertürk Şengel B, Başarı T, Tükenmez Tigen E, etal. Marmara Üniversitesi Pendik Eğitim ve AraştırmaHastanesi’nde 2014-2018 yılları arasındaki kronikhepatit C prevalansı, genotip dağılımı ve tedaviyanıtları. ANKEM Derg. 2020;34(1):13-7.
40. 40.Genç S, Uğur M, Uzunoğlu Karagöz E, Avcı E.Giresun ili hepatit C hastalarında genotipdağılımının araştırılması. Flora. 2020;25(4):549-54.
41. 41.Gökahmetoğlu S, Bozdayı M, Özbakır Ö, et al.Erciyes Üniversitesi’nde saptanan Hepatit C Virüsgenotipleri. Türk Mikrobiyol Cem Derg.2007;37(1):35-8.
42. 42.Gülseren YD, Esenkaya Taşbent F, Özdemir M,Feyzioğlu B. Kronik hepatit C infeksiyonu olanhastalarda hepatit C genotipleri: üç yıllık sonuçlarındeğerlendirilmesi. Flora. 2020;25(3):347-53.
43. 43.Gürbüz Y, Tülek NE, Tütüncü EE, et al. Evaluationof Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: AMulticenter, Retrospective Study. Balkan Med J.2016;33(1):18-26.
44. 44.Haciseyitoğlu D, Can Sarınoğlu R, Gözalan A,Batırel A, Söyletir G. Distribution of Hepatitis C VirusGenotypes in Patients Diagnosed with Hepatitis C inOur Hospital: 2015-2018. Mediterr J Infect MicrobAntimicrob. 2021;10:7.
45. 45.Harman R, Günal Ö, Özger S. GaziantepBölgesindeki Kronik Hepatit C Hastalarında HepatitC Virusu Genotip Dağılımı. Klimik Dergisi.2017;30(2):68-70.
46. 46.İba Yilmaz S, Erol S, Özbek A, Parlak M.Distribution of viral genotypes and extrahepaticmanifestations in patients with chronic hepatitis C in Eastern Turkey. Turk J Med Sci. 2015;45(1):70-5.
47. 47.Idilman R, Demir M, Aladag M, et al. Lowrecurrence rate of hepatocellular carcinomafollowing ledipasvir and sofosbuvir treatment in areal-world chronic hepatitis C patients cohort. J Viral Hepat. 2019;26(6):666-74.
48. 48. İrvem A, Özdil K, Kadanalı A, Karagöz G. HepatitisC Seropositivity and Distribution of HCV Genotypes.J Clin Anal Med. 2017;8(5): 425-7.
49. 49.Kabakçı Alagöz G, Karataylı SC, Karataylı E, et al.Hepatitis C virus genotype distribution in Turkeyremains unchanged after a decade: performance of phylogenetic analysis of the NS5B, E1, and 5'UTR regions in genotyping efficiency. Turk J Gastroenterol. 2014;25(4):405-10.
50. 50.Kalayci R, Altindiş M, Gülamber G, et al. Kronikhepatit B ve hepatit C'li hastalarda genotip dağilimive hepatit B olgularinda direnç paternininaraştirilmasi. Mikrobiyol Bul. 2010;44(2):237-43.
51. 51.Kandemir Ö, Gültekin O. Kronik Hepatit CEnfeksiyonlu Damar İçi Uyuşturucu MaddeKullanıcılarında Hepatit C Virüs GenotiplerininDağılımı. Turkiye Klinikleri J Med Sci.2017;37(1):21-6.
52. 52.Kandemir MH, Aladag M, Cagin YF, Yildirim HE,Sarici A. Efficacy of Posttransplant Ledipasvir-Sofosbuvir in the Treatment of Patients Who HaveUndergone Chronic Hepatitis C-Related LiverTransplant. Exp Clin Transplant. 2020.
53. 53. Kara H, İnan D, Özçelik Ö, et al. Frequency of HBV,HCV and HIV Infections and Determination of HCVGenotype Distribution in People Who Inject Drugs.Viral Hepat J. 2021;27(1):19-23.
54. 54.Karabulut N, Alacam S, Yolcu A, Onel M,Agacfidan A. Distribution of hepatitis C virusgenotypes in Istanbul, Turkey. Indian J MedMicrobiol. 2018;36(2):192-6.
55. 55.Kayman T, Polat C, Ergör G, Abacioğlu YH.Characterization of HCV genotype 4d infections inKayseri, Turkey. Turk J Med Sci. 2015;45(3):547-52.
56. 56.Keskın F, Çıftçı S, Türkoğlu S, Badur S.Transmission routes of chronic hepatitis C and theirrelation to HCV genotypes. Turk J Gastroenterol.2010;21(4):396-400.
57. 57.Keten D, Emin Ova M, Sirri Keten H, et al. ThePrevalence of Hepatitis B and C Among Prisoners inKahramanmaras, Turkey. Jundishapur J Microbiol.2016;9(2):e31598.
58. 58. Kırdar S, Yaşa MH, Aydın N, et al. The Distributionof Hepatitis C Virus Genotypes in Patients withChronic Hepatitis C Infection. Meandros Med Dent J.2015;16(3):108-13.
59. 59.Kirdar S, Sener AG, Cengiz M, Aydin N. Theprevalence of autoantibody and its relationship withgenotypes of hepatitis C virus in patients withchronic hepatitis C virus infection. APMIS.2016;124(11):979-84.
60. 60.Kirdar S, Aydin N, Tiryaki Y, et al. Dynamics ofHCV epidemiology in Aydin province of Turkey andthe associated factors. APMIS. 2018;126(2):109-13.
61. 61.Kirişçi Ö, Çalışkan A, Alkış Koçtürk S, ErdoğmusP, Gül M. Kahramanmaraş İli Hepatit C Virüs ileEnfekte Bireylerde Genotip Dağılımı ve GenotipinHCV-RNA Yükü ve ALT-AST İlişkisi. Viral Hepat J.2013;19(2):67-70.
62. 62.Kirişçi Ö, Çalışkan A. The Predominance ofGenotype 3 in Hepatitis C Virus in the Province ofKahramanmaras, Turkey/Genotype Distribution ofSyrian Refugee Patients with Hepatitis C inKahramanmaras Province. Jundishapur J Microbiol.2019;12(4):e80872.
63. 63.Tekin Koruk S, Koruk I, Calisir C, Karsen H. Thefollow-up results with sustained virologic responsein chronic hepatitis C patients in Şanlıurfa/Turkey.Journal of Microbiology and Infectious Diseases.2012;2(1):14-20.
64. 64.Kuru C, Hamidi AA. Genotype Distribution ofHepatitis C Virus and Demographic Features of ThePatients in The Province of Karabük. Viral Hepat J.2020;26(3):163-6.
65. 65.Küçköztaş MF, Ozgünes N, Yazici S. Kronikhepatit c'li hastalarda hepatit c virusu (HCV)genotipleri ile alanin aminotransferaz ve HCV-RNAdüzeyleri arasındaki ilişkinin araştırılması.Mikrobiyol Bul. 2010;44(1):111-5.
66. 66.Suntur BM, Kaya H, Eker HBŞ, et al. A cross-sectional study of real life data of HCV from Turkeysouth region. J Infect Dev Ctries. 2020;14(4):380-6.
67. 67.Sariguzel FM, Berk E, Gokahmetoglu S, Ercal BD,Celik I. Evaluation of the Abbott Real Time HCVgenotype II assay for Hepatitis C virus genotyping.Pak J Med Sci. 2015;31(5):1136-9.
68. 68.Nar H, Uyanıkoğlu A, Aydoğan T, Yenice N.Şanlıurfa Yöresi Hepatit C HastalarınınDeğerlendirilmesi. Viral Hepat J. 2013;19(2):62-6.
69. 69.Oral Zeytinli U, Muhterem Yucel F, DaldabanDincer S, et al. Distribution of Hepatitis C VirusGenotypes in the Region of ‘Istanbul NorthernAnatolian Association of Public Hospitals’. ViralHepat J. 2017;23(1):10-3.
70. 70.Öksüz Z, Üçbilek E, Serin MS, et al. Damar İçiUyuşturucu Madde Kullanan ve Kullanmayan Hepatit C Hastalarının Genotip Dağılımı ve Genotip ile Serum Aminotransferaz Düzeyleri Arasındaki Olası İlişkisi. Flora. 2022;27(1):11-20.
71. 71.Mıstanoğlu Özatağ D, Korkmaz P, Coşgun S,Konya P. Hemodiyaliz Uygulanan Kronik Hepatit CHastalarındaOmbitasvir/Paritaprevir/Ritonavir+DasabuvirTedavi Sonuçları. Flora. 2021;26(4):736-41.
72. 72.Ozbek E, Ozekinci T, Mese S, Atmaca S. HepatitisC Virus Genotypes are Changing in the Southeast ofTurkey. Biotechnol Biotechnol Equip.2009;23(4):1521-3.
73. 73.Özdoğan O, Yaraş S, Ateş F, Üçbilek E, Sezgin O,Altıntaş E. The impact of direct-acting antiviraltreatment on lipid metabolism and insulinresistance in chronic hepatitis C patients:temporary? permanent?. Turk J Gastroenterol.2020;31(5):384-92.
74. 74.Özdoğan O, Yaraş S. The Long-term (Over TenYears) Outcome of Hepatitis C patients withSustained Virologic Response Following Treatmentwith Pegylated Interferon + Ribavirin. Viral Hepat J.2020;26(1):22-7.
75. 75.Özer Etik D, Suna N, Öcal S, et al. SuccessfulTreatment With Direct-Acting Antiviral Agents ofHepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients. Exp ClinTransplant. 2019;17(1):52-8.
76. 76.Özger HS, Karaşahin Ö, Toy MA, İba Yılmaz S,Hızel K. Hepatitis C Prevalence and Responses toPegylated Interferon + Ribavirin Treatment AmongPrisoners. Viral Hepat J. 2017;23(3):71-5.
77. 77.Özkaya E, Buruk CK, Aydın F, Kaklıkkaya N,Baran I, Tosun İ. Distribution of Hepatitis C VirusGenotypes: 18-Year Experience in an AcademicCenter. Viral Hepat J. 2021;27(3):118-23.
78. 78.Özmen P, Gökahmetoğlu S. Hepatit C Virüs (HCV)Genotiplerinin “Reverse Hybridisation Strip Assay”ve DNA Dizi Analizi Yöntemleriyle Araştırılması.Mikrobiyol Bul. 2022;56(1):68-80.
79. 79.Oztürk AB, Doğan UB, Oztürk NA, et al. HepatitisC virus genotypes in Adana and Antakya regions ofTurkey. Turk J Med Sci. 2014;44(4):661-5.
80. 80.Rota S, Fidan I, Lale Z, et al. Determination ofHepatitis C Virus Genotype In Turkey byPyrosequencing Technology and its Associated With Viral Load and Sgot, Sgpt Levels. Acta Medica Mediterranea. 2013;29(3):397-402.
81. 81.Sağlik İ, Mutlu D, Öngut G, et al. AkdenizÜniversitesi Hastanesinde kronik hepatit Cenfeksiyonu olan hastalarda hepatit C virusgenotipleri: Beş yıllık sonuçların değerlendirilmesi.Mikrobiyol Bul. 2014;48(3):429-37.
82. 82.Sarı ND, Karataş A, İnci A, Yörük G. Yerli veYabancı Hastalarda Hepatit C Virüs GenotipDağılımının Değerlendirilmesi. Turkiye Klinikleri JMed Sci. 2020;40(2):148-53.
83. 83.Sarıgul F, Sayan M, User U, Oztoprak N.Evaluation of Direct Acting Antivirals Efficiency inTurkish Patients with Chronic Hepatitis C UnderStrict Rules. Hepat Mon. 2019;19(3):e62390.
84. 84.Sayan M, Yıldırım FS, Akhan S, et al. NS5Aresistance - associated substitutions in chronichepatitis C patients with direct acting antiviraltreatment failure in Turkey. Int J Infect Dis.2020;95:84-9.
85. 85.Selcuk H, Kanbay M, Korkmaz M, et al.Distribution of HCV genotypes in patients with end-stage renal disease according to type of dialysistreatment. Dig Dis Sci. 2006;51(8):1420-5.
86. 86.Selek MB, Baylan O, Karagöz E, Özyurt M.Changes in hepatitis C virus genotype distribution inchronic hepatitis C infection patients. Indian J MedMicrobiol. 2018;36(3):416-21.
87. 87.Süleymanlar İ, Karataş GU, Koçak H, Tekinalp G,Süleymanlar G. HCV(+) hemodiyaliz hastalarındaviremi, genotip ve karaciğer histolojisi arasındakiilişkiler. Ege Tıp Dergisi. 2010;49(2):101-6.
88. 88.Sanlidağ T, Akçali S, Ozbakkaloğlu B, Ertekin D,Akduman E. Manisa bölgesinde hepatit C virusgenotiplerinin dağilimi. Mikrobiyol Bul.2009;43(4):613-8.
89. 89.Şanlıdağ T, Sayan M, Akçalı S, Kasap E, Buran T,Arıkan A. Genotip 1 ile enfekte kronik hepatit Chastalarında NS3 inhibitörü ilaçların dirençmutasyonlarının belirlenmesi. Mikrobiyol Bul.2017;51(2):145-55.
90. 90.Tabak F, Şirin G, Demir M, et al. DemographicCharacteristics and Transmission Risk Factors ofPatients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial. Viral Hepat J.2021;27(3):109-17.
91. 91.Taheri S, Aygen B, Korkmaz K, Yıldız O, ZararsızG, Canatan H. Characterization of the Interleukin-28B Gene rs12979860 C/T Polymorphism inTurkish Chronic Hepatitis C Patients and HealthyIndividuals. Balkan Med J. 2015;32(2):147-55.
92. 92.Taskin MH, Gunal O, Arslan S, et al.Epidemiological findings on Hepatitis C infection ina tertiary level hospital in mid-northern Anatolia inTurkey: A four-year analysis. Trop Biomed.2020;37(1):227-36.
93. 93.Tezcan S, Ulger M, Aslan G, et al. Mersin ilindehepatit C virusu genotip dağılımının belirlenmesi.Mikrobiyol Bul. 2013;47(2):332-8.
94. 94.Tiftikci A, Atug O, Yilmaz Y, et al. Serum levels ofadipokines in patients with chronic HCV infection:relationship with steatosis and fibrosis. Arch MedRes. 2009;40(4):294-8.
95. 95.Tiryaki Y. Çetin Duran A. Özçolpan OO.Distribution of Hepatitis C Virus Genotypes in AydınProvince. Viral Hepat J. 2018;24(3):70-4.
96. 96. Tüzüner U, Saran Gülcen B, Özdemir M, FeyzioğluB, Baykan M. Seven-year Genotype DistributionAmong Hepatitis C Patients in a City in the CentralAnatolia Region of Turkey. Viral Hepat J.2018;24(1):12-7.
97. 97.Us T, Kaşifoğlu N, Aslan FG, Aslan M, Akgün Y,Durmaz G. The Distribution of Hepatitis C VirusGenotypes of Patients with Chronic Hepatitis CInfection in the Eskisehir Region of Turkey. J ClinAnal Med. 2017;8(2):88-91.
98. 98.Uzun B, Şener AG, Gungor S, Afşar I. Distributionof hepatitis C virus genotypes in western Turkey:experience of four years. Acta Medica Mediterranea.2014;30(5):1109-13.
99. 99.Üçbilek E, Abayli B, Koyuncu MB, et al.Distribution of hepatitis C virus genotypes amongintravenous drug users in the Çukurova region ofTurkey. Turk J Med Sci. 2016;46(1):66-71.
100. 100.Unal N, Bayık SA, Erdem F, Kucukcan A.Updated hepatitis C virus genotype distribution inAdana, Turkey and an investigation of theassociation between genotype and viral RNA load.Acta Medica Mediterranea. 2021;37(6):3303-8.
101. 101.Vatansever S, Pakoz ZB, Unsal B. Evaluation ofhepatitis A, B, and C serology in patients withcirrhosis and intensive alcohol consumption. NorthClin Istanb. 2018;5(2):109-13.
102. 102.Yamazhan T, Turan İ, Ersöz G, et al. Real-lifeexperience of ledipasvir and sofosbuvir single-tabletregimen among chronic hepatitis C patients inTurkey. Turk J Gastroenterol. 2020;31(3):239-45.
103. 103.Yetim A, Şahin M. Hepatitis C virus (HCV)infection in youth with illicit drug use:sociodemographic evaluation and HCV genotypeanalysis. Klimik Dergisi. 2018;31(3):190-4.
104. 104.Yildirim B, Durak H, Ozaras R, et al. Liversteatosis in hepatitis C positive hemodialysispatients and factors affecting IFN-2a treatment.Scand J Gastroenterol. 2006;41(10):1235-41.
105. 105.Yıldırım D, Hasbek M, Alkan S, Nur N.Relationship Between HCV RNA and Serum AlanineAminotransferase and HCV Genotype Distribution. JClin Anal Med. 2015;6(6):760-2. 106.Yildiz E, Oztan A, Sar F, et al. Molecularcharacterization of a full genome Turkish hepatitis Cvirus 1b isolate (HCV-TR1): a predominant viralform in Turkey. Virus Genes. 2002;25(2):169-77.
106. 107.Yildiz Kaya S, Mete B, Kaya A, Balkan İİ, SaltogluN, Tabak F. Evaluation of Chronic Hepatitis CPatients from Different Aspects Before the Use ofDirect Acting Antivirals. Viral Hepat J. 2017;23(1):6-9.
107. 108.Yilmaz A, Alagozlu H, Ozdemir O, Arici S. Effectsof the Chemokine Receptor 5 (CCR5)-Delta32Mutation on Hepatitis C Virus-Specific ImmuneResponses and Liver Tissue Pathology in HCVInfected Patients. Hepat Mon. 2014;14(7):e11283.
108. 109.Ziyade N, Yanılmaz Ö, Elgörmüş N, Arslan MN.Hepatitis C Virus Genotype Distribution in ForensicCases. Viral Hepat J. 2020;26(2):49-55.
109. 110.Ghaderi-Zefrehi H, Gholami-Fesharaki M,Sharafi H, Sadeghi F, Alavian SM. The Distribution ofHepatitis C Virus Genotypes in Middle EasternCountries: A Systematic Review and Meta-Analysis.Hepat Mon. 2016;16(9):e40357.
110. 111.Gower E, Estes C, Blach S, Razavi-Shearer K,Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-57.
111. 112.Polaris Observatory HCV Collaborators. Globalprevalence and genotype distribution of hepatitis Cvirus infection in 2015: a modelling study. LancetGastroenterol Hepatol. 2017;2(3):161-76.
112. 113.Roman F, Hawotte K, Struck D, et al. Hepatitis Cvirus genotypes distribution and transmission riskfactors in Luxembourg from 1991 to 2006. World JGastroenterol. 2008;14(8):1237-43.
113. 114.Sillanpää M, Huovinen E, Virtanen M, et al.P4:Epidemiology of hepatitis C virus infections inFinland between the years 1995 and 2011. J ViralHepat. 2013;20(Suppl. 3):17-8.
114. 115.Türkiye Göç İdaresi Başkanlığı. Düzensiz Göç.Available from: https://www.goc.gov.tr/duzensiz-goc-istatistikler (Access date: 15.12.2022).
115. 116.Katsoulidou A, Sypsa V, Tassopoulos NC, et al.Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specificincidence and molecular characterization ofgenotype 4 isolates. J Viral Hepat. 2006;13(1):19-27.
116. 117. Ansaldi F, Bruzzone B, Salmaso S, et al. Differentseroprevalence and molecular epidemiologypatterns of hepatitis C virus infection in Italy. J MedVirol. 2005;76(3):327-32.
117. 118.Saraswat V, Norris S, de Knegt RJ, et al.Historical epidemiology of hepatitis C virus (HCV) inselect countries - volume 2. J Viral Hepat.2015;22(Suppl 1):6-25.
118. 119.Niu Z, Zhang P, Tong Y. Age and genderdistribution of Hepatitis C virus prevalence andgenotypes of individuals of physical examination inWuHan, Central China. Springerplus.2016;5(1):1557.
119. 120.United Nations. United Nations Office on Drugsand Crime (UNODC). Available from:https://www.unodc.org/unodc/press/releases/2020/June/media-advisory---global-launch-of-the-2020-world-drug-report.html (Access date:15.12.2022).
120. 121.Türkiye Göç İdaresi Başkanlığı. Geçici Koruma.Available from: https://www.goc.gov.tr/gecici-koruma5638 (Access date: 15.12.2022).
121. 122.Antaki N, Haddad M, Kebbewar K, et al. Theunexpected discovery of a focus of hepatitis C virusgenotype 5 in a Syrian province. Epidemiol Infect.2009;137(1):79-84.
122. 123.Isenring E, Fehr J, Gültekin N, Schlagenhauf P.Infectious disease profiles of Syrian and Eritreanmigrants presenting in Europe: A systematic review. Travel Med Infect Dis. 2018;25:65-76.